NASDAQ:SLP Simulations Plus Q3 2026 Earnings Report $18.41 -0.02 (-0.11%) Closing price 09/22/2026 04:00 PM EasternExtended Trading$18.42 +0.00 (+0.03%) As of 09/22/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Simulations Plus EPS ResultsActual EPS$0.30Consensus EPS $0.23Beat/MissBeat by +$0.07One Year Ago EPSN/ASimulations Plus Revenue ResultsActual Revenue$21.89 millionExpected Revenue$20.90 millionBeat/MissBeat by +$990.00 thousandYoY Revenue GrowthN/ASimulations Plus Announcement DetailsQuarterQ3 2026Date7/9/2026TimeBefore Market OpensConference Call DateThursday, July 9, 2026Conference Call Time4:00PM ETUpcoming EarningsSimulations Plus' Q4 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled on Friday, October 23, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Simulations Plus Earnings HeadlinesCritical Analysis: Maravai LifeSciences (NASDAQ:MRVI) vs. Simulations Plus (NASDAQ:SLP)September 22 at 5:58 AM | americanbankingnews.comSimulations Plus Says FDA's Cosmetics Branch Adopts ADMET PredictorSeptember 18, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science BranchSeptember 17, 2026 | businesswire.comJohnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting DisclosuresSeptember 10, 2026 | globenewswire.comJohnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting DisclosuresAugust 27, 2026 | globenewswire.comSee More Simulations Plus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Simulations Plus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Simulations Plus and other key companies, straight to your email. Email Address About Simulations PlusSimulations Plus (NASDAQ:SLP) develops software and provides consulting services for pharmaceutical and biotechnology companies involved in drug discovery and development. Its modeling and simulation tools are designed to help researchers evaluate drug candidates, understand how medicines move through the body, assess safety risks and support decisions throughout the development process. The company’s products include GastroPlus, a platform used for physiologically based pharmacokinetic and biopharmaceutic modeling; ADMET Predictor, which helps predict absorption, distribution, metabolism, excretion and toxicity characteristics; and DILIsym, a software platform focused on drug-induced liver injury. Simulations Plus also offers additional modeling tools and scientific services covering pharmacokinetics, pharmacodynamics, toxicology and related areas. Founded in 1996, Simulations Plus serves pharmaceutical and biotechnology companies, contract research organizations, regulatory agencies and academic institutions. Its customer base is international, reflecting the company’s role in supporting drug research and development across major global pharmaceutical markets.View Simulations Plus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
